Colin Masters on Testing the right target and right drug at the right stage.
COMMENT This commentary is very germane. A few major issues deserve further elaboration. Testing the Aβ theory of AD (rather than the “amyloid hypothesis”) still has not been accomplished. The challenges are formidable. While the “right” target may not have been ...